{"id":"NCT00707980","sponsor":"Takeda","briefTitle":"Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","officialTitle":"A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-07","completion":"2010-08","firstPosted":"2008-07-02","resultsPosted":"2013-12-13","lastUpdate":"2013-12-13"},"enrollment":836,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","BrintellixÂ®"]}],"arms":[{"label":"Vortioxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.","primaryOutcome":{"measure":"Physical Examination Findings","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Vortioxetine","deltaMin":758,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":92,"countries":["United States","Australia","Croatia","France","Germany","Latvia","Lithuania","Malaysia","Netherlands","Poland","Russia","Serbia","South Africa","South Korea","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":834},"commonTop":["Nausea","Headache","Nasopharyngitis","Diarrhoea","Dizziness"]}}